Advertisement

The Egyptian hepatitis C programme: A model of HCV treatment intervention?

Published:February 03, 2018DOI:https://doi.org/10.1016/j.jhep.2018.01.021
      The Egyptian HCV epidemic, and the country’s response to it, are unlike any other country to date. Egypt has a very high burden of infection and disease: Egypt ranks 5th amongst all countries for the burden of disease from viral hepatitis,
      • Stanaway J.D.
      • Flaxman A.D.
      • Naghavi M.
      • Fitzmaurice C.
      • Vos T.
      • Abubakar I.
      • et al.
      The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.
      close to 15% of the adult population are seropositive for HCV and over four million individuals remain viraemic.
      Polaris Observatory HCV Collaborators
      Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
      • Kandeel Amr
      • Genedy Mohamad
      • El-Refai Samir
      • Funk Anna L.
      • Fontanet Arnaud
      • Talaat Maha
      The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment.
      As a lower middle-income country, Egypt is relatively poor with a gross national income per capita of $3,410 in 2016 according to the World Bank. Yet, it has strong political backing to tackle the HCV epidemic, stemming in part from the role of a national schistosomiasis programme in spreading the epidemic.
      • Elgharably Ahmed
      • Gomaa Asmaa I.
      • Crossey Mary M.E.
      • Norsworthy Peter J.
      • Waked Imam
      • Taylor-Robinson Simon D.
      Hepatitis C in Egypt – past, present, and future.
      To read this article in full you will need to make a payment
      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stanaway J.D.
        • Flaxman A.D.
        • Naghavi M.
        • Fitzmaurice C.
        • Vos T.
        • Abubakar I.
        • et al.
        The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.
        Lancet. 2016; 388: 1081-1088
        • Polaris Observatory HCV Collaborators
        Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
        Lancet Gastroenterol Hepatol. 2017; 2: 161-176
        • Kandeel Amr
        • Genedy Mohamad
        • El-Refai Samir
        • Funk Anna L.
        • Fontanet Arnaud
        • Talaat Maha
        The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment.
        Liver Int. 2017; 37: 45-53
        • Obach D.
        • Yazdanpanah Y.
        • Esmat G.
        • Avihingsanon A.
        • Dewedar S.
        • Durier N.
        • et al.
        How to optimize HCV treatment impact on life years saved in resource-constrained countries.
        Hepatology. 2015; 62: 31-39
        • Elgharably Ahmed
        • Gomaa Asmaa I.
        • Crossey Mary M.E.
        • Norsworthy Peter J.
        • Waked Imam
        • Taylor-Robinson Simon D.
        Hepatitis C in Egypt – past, present, and future.
        Int J Gen Med. 2017; 10: 1-6
        • Deuffic-Burban S.
        • Obach D.
        • Canva V.
        • Pol S.
        • Roudot-Thoraval F.
        • Dhumeaux D.
        • et al.
        Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
        J Viral Hepat. 2016; 23: 767-779
        • Zimmermann R.
        • Kollan C.
        • Ingiliz P.
        • Mauss S.
        • Schmidt D.
        • Bremer V.
        Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010–2015.
        J Hepatol. 2017; 67: 15-22
        • Mohamed Z.
        • Mbwambo J.
        • Shimakawa Y.
        • Poiteau L.
        • Chevaliez S.
        • Pawlotsky J.M.
        • et al.
        Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania.
        J Int AIDS Soc. 2017; 20: 21856

      Linked Article